Compare Merck & Co., Inc. (MRK) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Prologis Inc — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while Prologis Inc trades at $128.94 (market cap $122.87B). The key difference: Merck & Co., Inc. is far larger — about 2.9× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Prologis Inc for 102 Days on average.
| MRK | PLD | |
|---|---|---|
Market Cap | $351.28B | $122.87B |
Volume | 7,969,665 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $156.43 | $149.96 |
52-Week Low | $82.49 | $111.23 |
Typical Hold Time | 98 Days | 102 Days |
Enterprise Value | $398.04B | $157.61B |
Dividend Yield | 2.39% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Prologis (PLD) trades at $127.3, down 1.07% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and three consecutive quarterly EPS beats. The stock is supported by robust cash flow from operations of $5.01B in 2025 and positive leasing momentum highlighted by management. Recent news emphasizes growth from warehouse and data center demand, though technical indicators show selling pressure with key support at $126.
The outlook is mixed: analyst consensus is bullish with a $155.15 price target (59.52% buy ratings), but rising debt-to-asset ratios and bearish moving averages pose risks. Upside hinges on continued execution in logistics real estate, while macroeconomic sensitivity and valuation premiums require monitoring for sustained shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
